Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 9/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 9/20 | 0.68 |
| ▸ | CHRNB4 | P30926 | 6/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 6/20 | 0.38 |
| ▸ | RARG | P13631 | 2/20 | 0.37 |
| ▸ | RARB | P10826 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.35 |
| ▸ | CHRNG | P07510 | 2/20 | 0.35 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.35 |
| ▸ | CHRND | Q07001 | 2/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HTR1D | P28221 | 1/20 | 0.33 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2916099 | 0.91 | CHRNB2 (0.63) | CHRNB2CHRNA4CHRNB4CHRNA3RARG | |
| SCHEMBL23567637 | 0.91 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3CYP3A4 | |
| SCHEMBL6937141 | 0.91 | CHRNB2 (0.61) | CHRNB2CHRNA4CHRNB4CHRNA3CYP3A4 | |
| SCHEMBL2913382 | 0.84 | CHRNB2 (0.55) | CHRNB2CHRNA4CYP3A4CASP1RECQL | |
| SCHEMBL2061289 | 0.81 | CHRNB2 (0.79) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL29761232 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL2062192 | 0.81 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA1 | |
| SCHEMBL30015099 | 0.80 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CYP3A4 | |
| SCHEMBL25989709 | 0.80 | CHRNB2 (0.55) | CHRNB2CHRNA4CYP3A4CASP1RECQL | |
| SCHEMBL23530199 | 0.80 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104151132-B | The preparation method of amine | 先正达参股股份有限公司 | 2016-07-06 | — | — | CN | disclosed |
| EP-2297105-B1 | SUBSTITUTED AMIDES, METHOD OF MAKING, AND USE AS BTK INHIBITORS | GILEAD CONNECTICUT INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-2316809-B1 | Process for the preparation of benzonorbornane derivatives | SYNGENTA PARTICIPATIONS AG (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8680337-B2 | Process for the production of amides | Sungenta Limited (GB) | 2014-03-25 | — | — | US | disclosed |
| US-20130253225-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-8436037-B2 | Process for the production of amides | SYNGENTA LIMITED (GB) | 2013-05-07 | — | — | US | disclosed |
| EP-2316813-B1 | Process for the preparation of amines | SYNGENTA PARTICIPATIONS AG (CH) | 2013-04-03 | — | — | EP | disclosed |
| EP-1928838-B1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| EP-1963251-B1 | PROCESS FOR THE PREPARATION OF AMINES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-08-15 | — | — | EP | disclosed |
| US-20120065239-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA LIMITED (GB) | 2012-03-15 | — | — | US | disclosed |
| US-7781615-B2 | Process for the preparation of amines | SYNGENTA CROP PROTECTION, INC. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090221856-A1 | PROCESS FOR THE PREPARATION OF AMINES | SYNGENTA CROP PROTECTION, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| US-20090163569-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2009-06-25 | — | — | US | disclosed |
| EP-2066617-A1 | PROCESS FOR THE PRODUCTION OF AROMATIC AMINES IN THE PRESENCE OF A PALLADIUM COMPLEX COMPRISING A FERROCENYL BIPHOSPHINE LIGAND | Syngeta Participations AG (CH) | 2009-06-10 | — | — | EP | disclosed |
| EP-2014642-A1 | Process for the production of amines | Syngeta Participations AG (CH) | 2009-01-14 | — | — | EP | disclosed |
| EP-1963251-A2 | PROCESS FOR THE PREPARATION OF AMINES | Syngeta Participations AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1928838-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | Syngeta Participations AG (CH) | 2008-06-11 | — | — | EP | disclosed |
| WO-2008017443-A1 | PROCESS FOR THE PRODUCTION OF AROMATIC AMINES IN THE PRESENCE OF A PALLADIUM COMPLEX COMPRISING A FERROCENYL BIPHOSPHINE LIGAND | SYNGENTA PARTICIPATIONS AG (CH) | 2008-02-14 | — | — | WO | disclosed |
| WO-2007068417-A2 | PROCESS FOR THE PREPARATION OF AMINES | SYNGENTA PARTICIPATIONS AG (CH) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007031323-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | SYNGENTA PARTICIPATIONS AG. (CH) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065239-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | CFH, C5, CFB | CHRNB2 3072/4885CHRNA4 3201/4885CHRNB4 2861/4885 |
| US-20130253225-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | CFH, C5, CFB | CHRNB2 3175/4885CHRNA4 3287/4885CHRNB4 2973/4885 |
| US-20090221856-A1 | PROCESS FOR THE PREPARATION OF AMINES | HRH3, PAH, C1R | CHRNB2 1403/4885CHRNA4 2734/4885CHRNB4 2479/4885 |
| US-20090163569-A1 | PROCESS FOR THE PRODUCTION OF AMIDES | C5, CFH, C9 | CHRNB2 2716/4885CHRNA4 3024/4885CHRNB4 2724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.